Shuang Yang1, Pan Wang, Xiaobing Wang, Xiaomin Su, Quanhong Liu. 1. Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an, 710062, Shaanxi, China.
Abstract
OBJECTIVE: To prove that DNA damage, intracellular reactive oxygen species (ROS) generation and loss of mitochondrial membrane potential (MMP) are contributing factors for the inhibition of cell proliferation induced by doxorubicin (DOX) administration combined with microbubble-assisted low-level therapeutic ultrasound (US) in K562 cells. METHODS: 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay was adopted to examine cytotoxicity of different treatments. Changes on apoptosis and necrosis rates, DNA fragmentation, intracellular reactive oxygen species production, mitochondrial membrane potential, cellular membrane permeability and DOX-uptake were analysed by flow cytometry. Nuclear morphology changes were observed under a fluorescence microscope. Ultrasonic cavitation was measured by spectrofluorimetry. RESULTS: Under optimal conditions, MB-US significantly aggravated DOX-induced K562 cell death, especially necrosis, when compared with either monotherapy. Synergistic potentiation on DNA damage, ROS generation and MMP loss were observed. Ultrasonic cavitation effects, plasma membrane permeabilization and DOX-uptake were notably improved after MB-US exposure. CONCLUSIONS: MB-US could increase the susceptibility of tumours to antineoplastic drugs, suggesting a potential clinical method for US-mediated tumour chemotherapy. KEY POINTS: • Microbubble-ultrasound (MB-US) aggravated doxorubicin (DOX) induced K562 cell death, especially necrosis • MB-US synergistically potentiated DOX-initiated DNA damage, ROS generation and MMP loss • Ultrasonic cavitation effects, plasma membrane permeabilization and DOX-uptake were improved after treatment • MB-US holds significant potential for improving the efficacy of conventional chemotherapy.
OBJECTIVE: To prove that DNA damage, intracellular reactive oxygen species (ROS) generation and loss of mitochondrial membrane potential (MMP) are contributing factors for the inhibition of cell proliferation induced by doxorubicin (DOX) administration combined with microbubble-assisted low-level therapeutic ultrasound (US) in K562 cells. METHODS:3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay was adopted to examine cytotoxicity of different treatments. Changes on apoptosis and necrosis rates, DNA fragmentation, intracellular reactive oxygen species production, mitochondrial membrane potential, cellular membrane permeability and DOX-uptake were analysed by flow cytometry. Nuclear morphology changes were observed under a fluorescence microscope. Ultrasonic cavitation was measured by spectrofluorimetry. RESULTS: Under optimal conditions, MB-US significantly aggravated DOX-induced K562 cell death, especially necrosis, when compared with either monotherapy. Synergistic potentiation on DNA damage, ROS generation and MMP loss were observed. Ultrasonic cavitation effects, plasma membrane permeabilization and DOX-uptake were notably improved after MB-US exposure. CONCLUSIONS: MB-US could increase the susceptibility of tumours to antineoplastic drugs, suggesting a potential clinical method for US-mediated tumour chemotherapy. KEY POINTS: • Microbubble-ultrasound (MB-US) aggravated doxorubicin (DOX) induced K562 cell death, especially necrosis • MB-US synergistically potentiated DOX-initiated DNA damage, ROS generation and MMP loss • Ultrasonic cavitation effects, plasma membrane permeabilization and DOX-uptake were improved after treatment • MB-US holds significant potential for improving the efficacy of conventional chemotherapy.
Authors: N de Jong; P J Frinking; A Bouakaz; M Goorden; T Schourmans; X Jingping; F Mastik Journal: Ultrasound Med Biol Date: 2000-03 Impact factor: 2.998
Authors: Steliyan Tinkov; Conrad Coester; Susanne Serba; Nicolas A Geis; Hugo A Katus; Gerhard Winter; Raffi Bekeredjian Journal: J Control Release Date: 2010-09-22 Impact factor: 9.776
Authors: Evan C Unger; Thomas Porter; William Culp; Rachel Labell; Terry Matsunaga; Reena Zutshi Journal: Adv Drug Deliv Rev Date: 2004-05-07 Impact factor: 15.470
Authors: Cristina Carvalho; Renato X Santos; Susana Cardoso; Sónia Correia; Paulo J Oliveira; Maria S Santos; Paula I Moreira Journal: Curr Med Chem Date: 2009-09-01 Impact factor: 4.530
Authors: Bernadet D M Meijering; Lynda J M Juffermans; Annemieke van Wamel; Rob H Henning; Inge S Zuhorn; Marcia Emmer; Amanda M G Versteilen; Walter J Paulus; Wiek H van Gilst; Klazina Kooiman; Nico de Jong; René J P Musters; Leo E Deelman; Otto Kamp Journal: Circ Res Date: 2009-01-22 Impact factor: 17.367
Authors: Sachin S Thakur; Micheal S Ward; Amirali Popat; Nicole B Flemming; Marie-Odile Parat; Nigel L Barnett; Harendra S Parekh Journal: PLoS One Date: 2017-05-25 Impact factor: 3.240